BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.69
+0.06 (0.79%)
At close: Nov 6, 2026, 4:00 PM EST
7.71
+0.02 (0.26%)
After-hours: Nov 6, 2026, 7:30 PM EST
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, BioCryst Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $20.45. The average 1-year stock price forecast is 165.93% higher than the current stock price, while the lowest is $11 (+43.04%) and the highest is $32 (+316.12%).
Price Target: $20.45 (+165.93%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Maintains $11 | Hold | Maintains | $11 | +43.04% | Nov 5, 2026 |
| Wedbush | Wedbush | Buy Maintains $20 → $17 | Buy | Maintains | $20 → $17 | +121.07% | Nov 5, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 | Buy | Maintains | $30 | +290.12% | Oct 21, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $15 | Buy | Reiterates | $15 | +95.06% | Oct 9, 2026 |
| J.P. Morgan | J.P. Morgan | Hold Reiterates $12 → $13 | Hold | Reiterates | $12 → $13 | +69.05% | Sep 30, 2026 |
Financial Forecast
Revenue This Year
710.08M
from 874.84M
Decreased by -18.83%
Revenue Next Year
736.43M
from 710.08M
Increased by 3.71%
EPS This Year
0.75
from 0.63
Increased by 18.17%
EPS Next Year
0.83
from 0.75
Increased by 10.00%
EPS and Forward PE are based on non-GAAP adjusted numbers.